Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients

Sophie Kurk, Petra Peeters, Rebecca Stellato, B Dorresteijn, Pim de Jong, Marion Jourdan, Geert-Jan Creemers, Frans Erdkamp, Felix de Jongh, Peter Kint, Lieke Simkens, Bea Tanis, Manuel Tjin-A-Ton, Ankie Van Der Velden, Cornelis Punt, Miriam Koopman, Anne May, Sophie Kurk, Petra Peeters, Rebecca Stellato, B Dorresteijn, Pim de Jong, Marion Jourdan, Geert-Jan Creemers, Frans Erdkamp, Felix de Jongh, Peter Kint, Lieke Simkens, Bea Tanis, Manuel Tjin-A-Ton, Ankie Van Der Velden, Cornelis Punt, Miriam Koopman, Anne May

Abstract

Background: Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic colorectal cancer patients, but its mechanisms are unknown. We recently found, using data of the randomized phase 3 CAIRO3 study, that SMI loss was related with shorter time to disease progression and overall survival during first-line maintenance treatment with capecitabine + bevacizumab (CAP-B) or observation and during more intensive capecitabine + oxaliplatin + bevacizumab (CAPOX-B) reintroduction treatment. As a potential risk factor for reduced survival, we explored whether sarcopenia and SMI loss were associated with dose-limiting toxicities (DLTs) during CAP-B and CAPOX-B.

Methods: Sarcopenia status and SMI loss were assessed by using consecutive computed tomography scans. DLTs were defined as any dose delay/reduction/discontinuation of systemic treatment because of reported CTCAE (version 3.0) toxicities at the start or during treatment. Poisson regression models were used to study whether sarcopenia and body mass index (BMI) at the start of treatment and SMI and BMI loss during treatment were associated with DLTs.

Results: One hundred eighty-two patients (mean age 63.0 ± 8.8 years, 37% female) received CAP-B, and 232 patients (mean age 63.0 ± 9.0 years, 34% female) received CAPOX-B. At the start of CAP-B and CAPOX-B, 54% and 46% of patients were sarcopenic, respectively. Mean BMI was lower in sarcopenic patients, although patients were on average still overweight (sarcopenic vs. non-sarcopenic at the start of CAP-B 25.0 ± 3.9 vs. 26.7 ± 4.1 and CAPOX-B 25.8 ± 3.8 vs. 27.1 ± 3.8 kg/m2 ). Sarcopenia at the start of CAP-B was not associated with DLTs [relative risk 0.87 (95% confidence interval 0.64-1.19)], whereas patients with >2% SMI loss had a significantly higher risk of DLTs [1.29 (1.01-1.66)]. At the start of subsequent CAPOX-B, 25% of patients received a dose reduction, and the risk of dose reduction was significantly higher for patients with preceding SMI loss [1.78 (1.06-3.01)] or sarcopenia [1.75 (1.08-2.86)]. After the received dose reductions, sarcopenia or SMI loss was not significantly associated with a higher risk of DLTs during CAPOX-B [sarcopenia vs. non-sarcopenic: 0.86 (0.69-1.08) and SMI loss vs. stable/gain: 0.83 (0.65-1.07)]. In contrast, BMI (loss) at the start or during either treatment was not associated with an increased risk of DLTs.

Conclusions: In this large longitudinal study in metastatic colorectal cancer patients during palliative systemic treatment, sarcopenia and/or muscle loss was associated with an increased risk of DLTs. BMI was not associated with DLTs and could not detect sarcopenia or SMI loss. Prospective (randomized) studies should reveal whether normalizing chemotherapeutic doses to muscle mass or muscle mass preservation (by exercise and nutritional interventions) increases chemotherapeutic tolerance and improves survival.

Trial registration: ClinicalTrials.gov NCT00442637.

Keywords: Body composition; Chemotherapy; Dose-limiting toxicity; Metastatic colorectal cancer; Sarcopenia; Skeletal muscle mass.

Conflict of interest statement

B. Dorresteijn and M. Jourdan work at Nutricia Research. S.A. Kurk, P.H.M. Peeters, R.K. Stellato, P.A. de Jong, G.‐J.M. Creemers, F.L.G. Erdkamp, F.E. de Jongh, P.A.M. Kint, L.H.J. Simkens, B.C. Tanis, M.L.R. Tjin‐A‐Ton, A. Van Der Velden, C.J.A. Punt, M. Koopman, and A.M. May declare that they have no conflict of interest.40

© 2019 The Authors Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Figures

Figure 1
Figure 1
Flowchart. CAP‐B, capecitabine + bevacizumab; CAPOX‐B, capecitabine + oxaliplatin + bevacizumab; CT, computed tomography.
Figure 2
Figure 2
Associations of sarcopenia, skeletal muscle index (SMI) loss, and dose‐limiting toxicities (DLTs). This figure displays the association of sarcopenia and skeletal muscle index loss with dose‐limiting toxicities during treatment with capecitabine + bevacizumab (CAP‐B) and capecitabine + oxaliplatin + bevacizumab (CAPOX‐B). Relative risks (RRs) are determined by Poisson regression models. All models were adjusted for age, sex, resection primary tumour, and dose reduction during initial capecitabine + oxaliplatin + bevacizumab treatment. *Statistically significant results.

References

    1. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–1547.
    1. Kurk S, Peeters P, Dorresteijn B, de Jong P, Jourdan M, Kuijf H, et al. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle 2018;9:909–919.
    1. Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol 2017;28:2107–2118.
    1. Blauwhoff‐Buskermolen S, Versteeg KS, de van der Schueren MAE, den Braver NR, Berkhof J, Langius JAE, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1339–1344.
    1. Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J, et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS ONE 2015;10:1–12.
    1. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013;98:1012–1019.
    1. Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol 2015;93:203–210.
    1. Bonilla L, Ben‐Aharon I, Vidal L, Gafter‐Gvili A, Leibovici L, Stemmer SM. Dose‐Dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta‐analysis of randomized controlled trials. J Natl Cancer Inst 2010;102:1845–1854.
    1. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population‐based study. Lancet Oncol 2008;9:629–635.
    1. Antoun S, Borget I, Lanoy E. Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 2013;7:383–389.
    1. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 2014;66:583–589.
    1. Prado CMM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5‐fluorouracil‐based chemotherapy toxicity. Clin Cancer Res 2007;13:3264–3268.
    1. Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, et al. Lean body mass as an independent determinant of dose‐limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med 2016;5:607–616.
    1. Cespedes EM, Scd F, Lee VS, Prado CM. Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C‐SCANS study. Cancer 2017. Dec 15;123(24):4868–4877.
    1. Simkens LHJ, van Tinteren H, May A, ten Tije AJ, Creemers G‐JM, Loosveld OJL, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;6736:1–10.
    1. Kurk S, Peeters P, Dorresteijn B, de Jong P, Creemers MJ, Erdkamp F, et al. Impact of skeletal muscle index (SMI) loss during palliative systemic treatment (Tx) on time to progression and overall survival (OS) in metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2017;35:10087–10087 (manuscript submitted).
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2008;45:228–247.
    1. Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 2008;33:997–1006.
    1. Mosteller R. Simplified calculation of body‐surface area. N Engl J Med 1987;317:1098.
    1. Knol MJ, Le Cessie S, Algra A, Vandenbroucke JP, Groenwold RHH. Overestimation of risk ratios by odds ratios in trials and cohort studies: alternatives to logistic regression. CMAJ 2012;184:895–899.
    1. Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C‐SCANS study). Cancer Epidemiol Biomarkers Prev 2017;26:1008–1016.
    1. Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol 2015;41:186–196.
    1. Prado C, Maia Y, Ormsbee M, Sawyer M, Baracos V. Assessment of nutritional status in cancer—the relationship between body composition and pharmacokinetics. Anticancer Agents Med Chem 2013;13:1197–1203.
    1. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 2002;54:131–139.
    1. Crosby V, D'Souza C, Bristow C, Proffitt A, Hussain A, Potter V, et al. Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study. Support Care Cancer 2017;25:1257–1261.
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
    1. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 2012;10:80–89.
    1. Focht B, Clinton S, Devor S. Resistance exercise interventions during and following cancer treatment: a systematic review. J Support Oncol 2013;11:45–60.
    1. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non‐small‐cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double‐blind, phase 3 trials. Lancet Oncol 2016;17:519–531.
    1. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double‐blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14:335–345.
    1. Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double‐blind, placebo‐controlled, phase 3 study. Lancet Oncol 2017;18:192–201.
    1. Stewart Coats AJ, Ho GF, Prabhash K, von Haehling S, Tilson J, Brown R, et al. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial). J Cachexia Sarcopenia Muscle 2016;7:355–365.
    1. Wright TJ, Dillon EL, Durham WJ, Chamberlain A, Randolph KM, Danesi C, et al. A randomized trial of adjunct testosterone for cancer‐related muscle loss in men and women. J Cachexia Sarcopenia Muscle 2018;9:482–496.
    1. Golan T, Geva R, Richards D, Madhusudan S, Lin BK, Wang HT, et al. LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial. J Cachexia Sarcopenia Muscle 2018;9:871–879.
    1. Brown JC, Cespedes Feliciano EM, Caan BJ. The evolution of body composition in oncology‐epidemiology, clinical trials, and the future of patient care: facts and numbers. J Cachexia Sarcopenia Muscle 2019;9:1200–1208.
    1. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36:11–48.
    1. Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, et al. Omega‐3 fatty acids are protective against paclitaxel‐induced peripheral neuropathy: a randomized double‐blind placebo controlled trial. BMC Cancer 2012;12:1–8.
    1. Sánchez‐lara K, Turcott JG, Juárez‐hernández E, Nuñez‐valencia C, Villanueva G, Guevara P, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non‐small cell lung cancer: randomised trial. Clin Nutr 2014;33:1017–1023.
    1. van der Werf A, Blauwhoff‐Buskermolen S, Langius JAE, Berkhof J, Verheul HMW, de van der Schueren MAE. The effect of individualized NUTritional counseling on muscle mass and treatment outcome in patients with metastatic COLOrectal cancer undergoing chemotherapy: a randomized controlled trial protocol. BMC Cancer 2015;15:1–7.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2017. J Cachexia Sarcopenia Muscle 2017;8:1081–1083.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren